Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was
adopted by WHO as a strategy to reduce HIV incidence. Although shown to be highly …

Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Abstract Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1)
nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that …

Worldwide, women face compounding reproductive health risks, including human
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended …

When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of
HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and …

Long-acting and extended-release formulations represent one of the most important
approaches to improving the treatment and prevention of chronic HIV infection. Long-acting …

Combined antiretroviral therapy (cART) is treatment with a combination of several
antiretroviral drugs that block multiple stages in the virus replication cycle. An estimated 60 …

Introduction Despite significant advances in treatment and prevention of HIV-1 infection,
poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major …

We describe the in vitro and in vivo evaluation of a subcutaneous reservoir implant
delivering tenofovir alafenamide hemifumarate (TAF) for the prevention of HIV infection …

Islatravir for the treatment and prevention of infection wit... : Current Opinion in HIV and
AIDS Islatravir for the treatment and prevention of infection with the human …